Does FDA Control Generic Drug Prices? Not Entirely
Executive Summary
Generic firms are finding the pricing pressure receding somewhat in their industry - but only because regulatory pressures are making it difficult to stay on the market
You may also be interested in...
ANDA User Fees: Industry Takes Holistic Approach, Wants Whole New Office
The generics industry is pushing FDA to create a commissioner-level office dedicated to handling issues related to ANDAs during negotiations over the creation a user fee program for generic drugs
ANDA User Fees: Industry Takes Holistic Approach, Wants Whole New Office
The generics industry is pushing FDA to create a commissioner-level office dedicated to handling issues related to ANDAs during negotiations over the creation a user fee program for generic drugs
Ranbaxy Loses Tamsulosin Launch Opportunity To Impax; Analysts Raise Doubts About Nexium, Lipitor
MUMBAI - It's been a tricky and awkward situation for Ranbaxy since it admitted at the last minute to losing a big opportunity of launching the first generic version of prostate enlargement drug Flomax (tamsulosin) in the United States. On March 2, Impax launched the generic variant of the nearly $2 billion blockbuster drug as part of an October 2009 patent settlement inked with Boehringer Ingelheim